The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
July 26th 2024
The application was supported by positive data of KYV-101 in patients with stiff-person syndrome treated in Germany under a named-patient treatment option.
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, ...
September 16, 2024
Register Now!
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Amneal Announces Complete Response Resubmission for Parkinson Therapy IPX203
February 8th 2024IPX203, a novel, oral formulation of carbidopa/levodopa, had its new drug application supported by findings from the phase 3 RISE-PD study, where treated patients showed greater ON time than immediate-release CD/LD.
NeuroVoices: Joe Burnett, on FDA Clearance of SmartFrame OR Stereotactic System
February 7th 2024The chief executive officer of ClearPoint Neuro provided clarity on how the recently approved SmartFrame system can enhance the efficiency of operating room procedures, allowing for flexible workflows and image-based corrections.
Realistic Expectations, Limitations With Gene Therapy for Parkinson Disease: Ignacio Mata, PhD
February 4th 2024The associate professor of neurology at the Cleveland Clinic Learner Institute discussed some of the complexities with genetics in Parkinson disease and the ideas behind developing and administering targeted gene therapies. [WATCH TIME: 4 minutes]
Expanding the Genetic Pool of Non-European Populations in Parkinson Disease: Ignacio Mata, PhD
January 30th 2024The associate professor of neurology at the Cleveland Clinic Lerner Institute provided insight on a recently published meta-analysis identifying independent genome-wide significant loci whose expression is associated with Parkinson disease risk. [WATCH TIME: 5 minutes]
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhD
January 29th 2024The senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
Easing Neurosurgery With Newly Approved SmartFrame OR Stereotactic System: Joe Burnett
January 28th 2024The chief executive officer of ClearPoint Neuro discussed how the company’s SmartFrame OR Stereotactic System can facilitate neurosurgery and the next steps in integrating it into clinical settings. [WATCH TIME: 4 minutes]
Caregiving Youth: A Call to Action for Improved Support
January 27th 2024A systematic approach to understanding the needs of the caregiving youth—a growing and less-studied population of caregivers—is needed to better tailor interventions, provide support, and improve care to patients and their families.
Neuroprotectant Mechanism of Action of Stroke Exosome AB126: Stephen From
January 26th 2024The chief executive officer of Aruna Bio discussed the mechanism of action behind AB126 and how its anti-inflammatory and neuroprotective properties may be effective in treating acute ischemic stroke. [WATCH TIME: 4 minutes]
Case Study Shows ITPR1 Variant Associated With Spinocerebellar Ataxia Type 29
January 25th 2024In a recent case study, clinical exome sequencing exposed a heterozygous missense mutation in the ITPR1 gene where patients showed craniofacial abnormalities as well as spinocerebellar ataxia-like syndrome.
FGF14 GAA Repeat Expansions Frequency Shows an Association With Ataxia Syndromes
January 20th 2024In a study cohort, investigators observed the frequency of FGF14 GAA repeat expansions in 17 patients, prompting the inclusion of GAA-FGF14-related disease in the differential diagnosis of ataxia related syndromes.
Quality of Life in Parkinson Disease Maintained After 5 Years of Subthalamic DBS
January 20th 2024The study provided the first class IIb evidence of the long-term benefits of deep brain stimulation in patients with Parkinson disease, emphasized by improved quality of life and reduced medication requirements.
Dual-Task Training Improves Balance in Pediatric Ataxia Following Medulloblastoma Resection
January 19th 2024A recent study demonstrated the superior efficacy of a dual-task training program over traditional physical therapy in improving balance and cognitive function in pediatric patients with ataxia following medulloblastoma resection.
A Clinical Preview of 2024 for Movement Disorders: Kelly Papesh, DNP, APRN, FNP-BC
January 15th 2024The clinical director of Parkinson & Movement Disorder Alliance shared her thoughts on potential therapies to increase management care options for patients with Parkinson disease. [WATCH TIME: 5 minutes]